Navigation Links
Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival
Date:2/17/2009

BETHESDA, Md., Feb. 17 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO; AIM: NWBT and NWBS) ("NWBT" or the "Company") today announced further long-term follow-up data, for the second half of 2008, from its prior Phase I and Phase I/II clinical trials with DCVax(R)-Brain in patients with Glioblastoma multiforme, the most rapid and lethal type of brain cancer. During the update period from June 15, 2008, through January 1, 2009, none of the twenty patients treated with standard of care plus DCVax(R)-Brain died. So far, now, 68% of patients treated with DCVax(R)-Brain have lived more than 2 years, 63% have lived more than 2-1/2 years, 53% have lived more than 3 years, 35% have lived more than 4 years and 25% have lived more than 5 years. In contrast, patients who receive full standard of care (surgery, radiation and chemotherapy) without DCVax(R)-Brain have a median survival of only 14.6 months, and less than 5% of these patients are typically alive at 5 years.

In addition to there being no deaths among the DCVax(R)-Brain treated patients during the 2008 update period, only two of the twenty patients experienced progression (recurrence) of their brain cancer. One of these two patients had been disease free for nearly 6 years (70 months) at the time of their progression, and the other patient had been disease free for more than 4 years (50 months). In contrast, the usual time to progression (recurrence) in GBM, with full standard of care treatment but without DCVax(R)-Brain, is only 6.9 months.

    In other results from the 2008 update data period:

    -- 95% of DCVax(R)-Brain treated patients have lived longer than the
       median survival of 14.6 months with existing standard of care
       treatment;
    -- Likewise, 95% of DCVax(R)-Brain treated patients have been free of
       disease progression (recurrence) for longer than the median progression
       free s
'/>"/>
SOURCE Northwest Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
3. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
6. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
7. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... BARCELONA , Spanien, September 2, ... -- Das auf dem ESC-Kongress 2014 ... die Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten ...    Die Daten ... eingetragenen Patienten, einer innovativen und unabhängigen ...
(Date:9/2/2014)... Sept. 2, 2014 Particle Sciences, the leading ... investment in development and manufacturing capabilities with the addition ... Mueller , Particle Sciences, Associate Director Clinical Production, "The ... clean room square footage, equipment and staff across the ... company now has over 6000ft 2 of operating ...
(Date:9/2/2014)... Sept. 2, 2014  Edison Nation Medical, the ... with the American Association for Respiratory Care ( ... care specialists. Edison Nation Medical, which brings 12+ ... to commercialize their innovation ideas, will work with ... more than 50,000 respiratory therapists in bringing their ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3
... N.J., Nov. 9 Unwavering from its pursuit of ... climate, Lutronic, Inc., a leading developer of high quality ... fractional CO2 device priced at under $50,000. , ... to Lutronic,s fractional technology including scanning and stamping operation ...
... (NYSE Amex: KAD ), a leading provider of ... brand, has appointed Stephen Goldsmith to its Board of ... his resignation from the Board. , ... is the Daniel Paul Professor of Government and Director ...
Cached Medicine Technology:Lutronic(R) Unleashes the New MOSAIC CO2 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 2Arcadia Resources Names Stephen Goldsmith to Board of Directors 3
(Date:9/2/2014)... News) -- A leading group of oncologists has released ... of advanced breast cancer. HER2-negative breast tumors ... the HER2 protein, the American Society of Clinical Oncology ... Almost 80 percent of women with advanced breast cancer ... this guideline, our aim is to improve both the ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
(Date:9/2/2014)... less intensive (and expensive) practice patterns appear to consistently ... unnecessary and excessive medical care, according to a new ... concern about the costs and harms of medical care ... the provision of unnecessary care," said lead author Brenda ... Institute for Health Policy & Clinical Practice. , ...
(Date:9/2/2014)... 02, 2014 Anti-aging is proving ... services such as anti-wrinkle treatments and products, hair ... and breast augmentation becoming much sought after worldwide. ... market intelligence firm Transparency Market Research, the global ... grow to USD 191.7 billion by 2019, from ...
(Date:9/2/2014)... When weather conditions are right, tornadoes can occur anywhere and ... of destruction. In fact, the United States leads the world ... year. Rainbow International offers the following safety tips on how ... , Select a safe place such as a basement, ... windows to stay during the storm. If a tornado is ...
Breaking Medicine News(10 mins):Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 2Health News:Global Anti-aging Market Research Report 2018 by Transparency Market Research 3Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2
... 10 GeneGo, Inc., a leading,provider of software and ... announced that A*STAR,s Singapore Immunology Network (SIgN) has become ... have access,to GeneGo,s MetaCore, training and advanced support. ... SIgN researchers. , ...
... brings together in one resource the necessary information to make ... any time of year , , ... pediatrician to identifying the city,s best otolaryngologist (and figuring out ... a daunting task, especially if you,re not an MD, a ...
... to provide national contracting portfolio, e-commerce exchange and clinical services ... ... announced today that Jordan Health Systems in Plymouth, Massachusetts has ... supply chain services to help manage its approximate $35 ...
... , TUCSON, Ariz., Dec. 10 ... ) today announced that its Board of Directors has adopted ... will receive rights to purchase shares of the Company,s Series ... "In this period of unprecedented market volatility where ...
... December 10 ICON plc (NASDAQ:, ... development,services to the pharmaceutical, biotechnology and medical ... division has launched a new cardiac,echocardiography analysis ... (ECHO) images to be viewed, measured and ...
... over two and a half times more likely to ... a motor vehicle crash compared with normal weight children, ... Bloomberg School of Public Health,s Center for Injury Research ... likely to experience injury to any body part following ...
Cached Medicine News:Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Vitals Launches Free eBook to Help Consumers Find 'Dr. Right' 2Health News:Jordan Health Systems Selects Broadlane to Provide Comprehensive Supply Chain Services 2Health News:Jordan Health Systems Selects Broadlane to Provide Comprehensive Supply Chain Services 3Health News:Providence Service Corporation Adopts Shareholder Rights Plan 2Health News:Providence Service Corporation Adopts Shareholder Rights Plan 3Health News:ICON Medical Imaging Launches New Cardiac Echocardiography Analysis Software 2Health News:Overweight children at increased risk of arm and leg injuries following motor vehicle crash 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: